ATHA Athira Pharma

Athira Pharma to Host Fourth Quarter and Full Year 2021 Financial Results and Business Update Conference Call on March 24, 2022

Athira Pharma to Host Fourth Quarter and Full Year 2021 Financial Results and Business Update Conference Call on March 24, 2022

BOTHELL, Wash., March 17, 2022 (GLOBE NEWSWIRE) --  (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced it will report financial results for the fourth quarter and full year ended December 31, 2021 and provide a business update on Thursday, March 24, 2022 following the close of the U.S. financial markets. Athira will host a conference call to discuss these results on Thursday, March 24, 2022 at 4:30 pm Eastern time (1:30 pm Pacific time).

In order to participate in the conference call, please dial 833-614-1520 (domestic) or 516-575-8710 (international) and refer to conference ID 3597642. The live webcast can be accessed under "Events & Presentations" in the Investors section of the Company's website at , where it will also be archived.

About Athira Pharma, Inc.

Athira Pharma, Inc., headquartered in the Seattle area, is a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration. Athira aims to provide rapid cognitive improvement and alter the course of neurological diseases with our novel mechanism of action. Athira is currently advancing its lead therapeutic candidate, fosgonimeton (ATH-1017), a novel small molecule for Alzheimer’s and Parkinson’s disease dementia and Dementia with Lewy bodies. For more information, visit . You can also follow Athira on ,  and @athirapharma on  and .

Investor & Media Contact:

Julie Rathbun

Athira Pharma

206-769-9219



EN
17/03/2022

Underlying

ATHAAthira Pharma

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Athira Pharma

 PRESS RELEASE
Free
ATHA ATHIRA PHARMA

LeonaBio Appoints Industry Veteran Mark F. Kubik as Chief Business Off...

LeonaBio Appoints Industry Veteran Mark F. Kubik as Chief Business Officer Brings more than 25 years of biopharma business development and corporate strategy expertise BOTHELL, Wash., Feb. 03, 2026 (GLOBE NEWSWIRE) -- LeonaBio, Inc. (NASDAQ: LONA), a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high unmet medical needs, today announced the appointment of Mark F. Kubik as Chief Business Officer. In this role, Mr. Kubik will lead LeonaBio’s business development strategy and execution, with responsibility for licensing, partn...

February 3, 2026 1 EN
 PRESS RELEASE
Free
ATHA ATHIRA PHARMA

Athira Pharma Announces Name Change to LeonaBio, Inc. with New Ticker ...

Athira Pharma Announces Name Change to LeonaBio, Inc. with New Ticker “LONA” New name to reflect recent transformative acquisition of rights to Phase 3 program in metastatic breast cancer and commitment to continued leadership, resilience and innovation BOTHELL, Wash., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high unmet medical needs, today announced that it has changed its name to LeonaBio, Inc. The name change aligns with the Company’s transforma...

January 9, 2026 1 EN
 PRESS RELEASE
Free
ATHA ATHIRA PHARMA

Athira Pharma Announces Exclusive License to Lasofoxifene Phase 3 Deve...

Athira Pharma Announces Exclusive License to Lasofoxifene Phase 3 Development Program for Metastatic Breast Cancer Candidate and a Financing for up to $236 Million Phase 3 Development Program of Novel Selective Estrogen Receptor Modulator (SERM) Represents Potential Multi-Billion Dollar Opportunity as Treatment Option for Patients with ESR1-Mutations Financing Co-Led by Commodore Capital, Perceptive Advisors and TCGX Supports Development of Lasofoxifene through Phase 3 Clinical Topline Data Readout and Regulatory Milestones Conference Call Today at 8:30 am Eastern Time BOTHELL, Wash., De...

December 18, 2025 1 EN
 PRESS RELEASE
Free
ATHA ATHIRA PHARMA

Athira Pharma Reports Third Quarter 2025 Financial Results and Provide...

Athira Pharma Reports Third Quarter 2025 Financial Results and Provides Business Update Continuing to explore strategic alternatives focusing on maximizing stockholder value   Presented results from Phase 1 clinical trial of ATH-1105 in healthy volunteers demonstrating a favorable safety and tolerability profile as well as dose proportional pharmacokinetics and CNS penetration, supporting continued clinical development  BOTHELL, Wash., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a clinical stage biopharmaceutical company focused on developing small molecules to...

November 6, 2025 1 EN
 PRESS RELEASE
Free
ATHA ATHIRA PHARMA

Athira Pharma Announces Reverse Stock Split

Athira Pharma Announces Reverse Stock Split BOTHELL, Wash., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (“Athira” or “Company”) (NASDAQ: ATHA), a clinical stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that it will effect a 10-for-1 reverse stock split of Athira’s issued and authorized common stock. Athira’s stockholders previously approved the reverse stock split and granted the board of directors the authority to determine the exact split ratio and when to proceed with the reverse st...

September 11, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch